Search

A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer. The new international research found that the drug pertuzumab (Perjeta®) significantly improved invasive-disease-free survival (IDFS) in patients with operable HER2-positive breast cancer when added to trastuzumab (Herceptin®) and chemotherapy. The findings of this study were presented at the American Society of Clinical Oncology annual meeting today in Chicago.

… Monday, June 5, 2017 A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD , Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer

MSK introduced its first new creative campaign in nearly two decades. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York.

… Tuesday, September 2, 2014 Memorial Sloan Kettering Cancer Center today introduced its first new creative campaign in nearly two decades: More Science. Less Fear. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York. MSK

Four summer students -- Jeannie Camarillo, Emily Grzybowski, Nathaniel Kim, and Daniel Triner -- were named 2010 Rubin and Sarah Shaps Scholars.

… Thursday, September 1, 2011 Four summer students are named Rubin and Sarah Shaps Scholars each summer. Students are selected on the basis of their outstanding undergraduate credentials and their performance in our summer program. Jeannie Camarillo, a junior majoring in physiology at the University of

MSK physicians and scientists are involved in notable research to be presented at the meeting and are available to comment on a variety of topics within leukemia, lymphoma, and multiple myeloma.

… Friday, December 4, 2020 Thousands of oncology experts from around the world will tune in December 5-8, 2020 for The American Society of Hematology’s (ASH) Annual Meeting and Exposition . For more than 60 years, the (ASH) Annual Meeting and Exposition has been the world’s most comprehensive hematology

MSK investigators report a new tool that may help them determine the origin of some metastatic tumors, potentially leading to better targeted treatments.

… Thursday, November 14, 2019 Summary Despite many advances in diagnostic technologies, the original site of some cancers will never be found. A new tool may help. Experts estimate that between 2 and 5% of all cancers are classified as cancer of unknown primary (CUP) , also called occult primary cancer

The BRCA Founder Outreach study was recently launched to look at how patients undergo genetic screenings for cancer.

… Wednesday, April 25, 2018 Summary A new study led by MSK and three other cancer centers is looking at different aspects of testing for cancer genes. In March 2018, the US Food and Drug Administration approved an at-home, mail-in kit that tests for some of the inherited mutations in the genes BRCA1 and

Global regulatory harmonization of clinical trials provides significant opportunity to accelerate access to cancer treatments to benefit all of humanity. This was the theme of the fifth annual MSK-CTONG Symposium, hosted online for a global audience of 20,000 from Guangzhou, China and New York on December 2, 2022.

… Wednesday, December 28, 2022 Global regulatory harmonization of clinical trials provides significant opportunity to accelerate access to cancer treatments to benefit all of humanity. This was the theme of the fifth annual MSK-CTONG Symposium, hosted online for a global audience of 20,000 from Guangzhou

Kimberly Feigin, MD, has been named Chief of the Breast Imaging Service within the Department of Radiology.

… Monday, January 13, 2025 Kimberly Feigin, MD, has been named Chief of the Breast Imaging Service within the Department of Radiology . Dr. Feigin has been a member of the service for 22 years and most recently served as Interim Chief. Dr. Feigin also serves as the Head of Breast Imaging Quality Assurance

Alexander Rudensky’s research focuses on the role of a subset of white blood cells called regulatory T cells, which are believed to suppress the immune system’s ability to fight tumors.

… Monday, December 16, 2013 Summary Alexander Rudensky’s research focuses on the role of a subset of white blood cells called regulatory T cells, which are believed to suppress the immune system’s ability to fight tumors. Alexander Rudensky is Chair of the Immunology Program in the Sloan Kettering Institute

A new strategy for treating pediatric cancers involves preventing cells from repairing their own DNA.

… Wednesday, November 1, 2017 Summary A majority of childhood solid tumors appear to be caused when a protein called PGBD5 scrambles DNA segments to cause genetic mutations. This PGBD5 activity in cancer cells also creates many breaks in the DNA, which the cells must repair in order to survive. A new treatment